Last reviewed · How we verify
ABP 206
ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells.
ABP 206 is a biosimilar of bevacizumab that inhibits vascular endothelial growth factor (VEGF) to block tumor angiogenesis and reduce blood supply to cancer cells. Used for Metastatic colorectal cancer, Non-squamous non-small cell lung cancer, Metastatic breast cancer.
At a glance
| Generic name | ABP 206 |
|---|---|
| Sponsor | Amgen |
| Drug class | VEGF inhibitor (monoclonal antibody); bevacizumab biosimilar |
| Target | VEGF (Vascular Endothelial Growth Factor) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
ABP 206 is a monoclonal antibody that binds to and neutralizes VEGF, a key signaling protein that promotes the formation of new blood vessels. By blocking VEGF, the drug prevents tumors from developing their own blood supply, thereby inhibiting tumor growth and metastasis. As a biosimilar to Avastin (bevacizumab), it is designed to have equivalent efficacy and safety to the reference biologic.
Approved indications
- Metastatic colorectal cancer
- Non-squamous non-small cell lung cancer
- Metastatic breast cancer
- Renal cell carcinoma
Common side effects
- Hypertension
- Proteinuria
- Bleeding/hemorrhage
- Thromboembolic events
- Gastrointestinal perforation
- Wound healing complications
Key clinical trials
- Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer (PHASE2)
- Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy (PHASE3)
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma (PHASE1, PHASE2)
- Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer (PHASE1)
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma (PHASE2)
- Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN (PHASE1, PHASE2)
- Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ABP 206 CI brief — competitive landscape report
- ABP 206 updates RSS · CI watch RSS
- Amgen portfolio CI